KLP Kapitalforvaltning AS Invests $1.51 Million in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

KLP Kapitalforvaltning AS bought a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 41,700 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,508,000.

Several other hedge funds have also recently added to or reduced their stakes in SUPN. Smartleaf Asset Management LLC grew its stake in shares of Supernus Pharmaceuticals by 219.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 870 shares during the period. Newbridge Financial Services Group Inc. acquired a new stake in Supernus Pharmaceuticals in the 4th quarter valued at $72,000. Venturi Wealth Management LLC bought a new stake in Supernus Pharmaceuticals in the fourth quarter valued at $92,000. KBC Group NV raised its stake in Supernus Pharmaceuticals by 53.1% during the fourth quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock worth $97,000 after acquiring an additional 929 shares in the last quarter. Finally, Janney Montgomery Scott LLC bought a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at $211,000.

Insiders Place Their Bets

In other news, SVP Jonathan Rubin sold 927 shares of the company’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the transaction, the senior vice president now owns 7,853 shares of the company’s stock, valued at $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Padmanabh P. Bhatt sold 700 shares of Supernus Pharmaceuticals stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total value of $27,734.00. Following the completion of the sale, the vice president now owns 10,149 shares of the company’s stock, valued at approximately $402,103.38. The trade was a 6.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,104 shares of company stock valued at $440,263 in the last 90 days. 9.30% of the stock is currently owned by insiders.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock opened at $32.29 on Friday. The stock’s fifty day moving average is $35.15 and its 200-day moving average is $35.01. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $40.28. The stock has a market capitalization of $1.80 billion, a PE ratio of 30.18 and a beta of 0.83.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on SUPN shares. Cantor Fitzgerald reiterated a “neutral” rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. StockNews.com lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, March 24th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.